Today: 30 April 2026
Browse Category

NSE:GRSE 28 November 2025 - 8 December 2025

Garden Reach Shipbuilders & Engineers (GRSE) Stock Today: Price Action, Q2 FY26 Results, Defence Order Book and 12‑Month Forecasts (8 December 2025)

Garden Reach Shipbuilders & Engineers (GRSE) Stock Today: Price Action, Q2 FY26 Results, Defence Order Book and 12‑Month Forecasts (8 December 2025)

GRSE shares fell about 2.5–3% intraday to around ₹2,400 on 8 December 2025, extending a five-session slide of roughly 11–12%. Despite the pullback, the stock remains up 53% year-to-date and reported Q2 FY26 net profit of ₹154 crore, up 57% year-on-year. The board declared an interim dividend of ₹5.75 per share. Market cap stands near ₹27,500 crore.
8 December 2025
···
GRSE Share Price Today, 28 November 2025: Garden Reach Shipbuilders Stock Edges Higher on Strong Q2 Earnings and Defence Theme

GRSE Share Price Today, 28 November 2025: Garden Reach Shipbuilders Stock Edges Higher on Strong Q2 Earnings and Defence Theme

GRSE shares rose 1.6% on the NSE Friday, closing near ₹2,831 after a strong Q2 FY26 earnings report earlier this month. The stock traded between ₹2,781.20 and ₹2,864.00 on volumes of about 1 million shares. Market cap stands near ₹32,400 crore, with the stock up about 65% over one year. No new exchange filings were reported during the session.
28 November 2025
·

Stock Market Today

  • Novo Nordisk Shares Undervalued Amid Year-Long Decline, DCF Model Shows
    April 30, 2026, 4:51 PM EDT. Novo Nordisk's (NYSE:NVO) stock price has dropped 37.4% over the past year, underperforming its pharmaceutical peers. Despite this, a Discounted Cash Flow (DCF) analysis estimates the stock is undervalued by 63.9%, suggesting its intrinsic value could be around US$111.54 per share versus the recent US$40.29 close. The company's price-to-earnings (P/E) ratio stands at 11.06x, below both the industry average of 15.84x and peer average of 19.24x, indicating a relatively lower share price relative to earnings. This gap points to potential misalignment between market pricing and Novo Nordisk's long-term free cash flow prospects and earnings growth expectations. Investors may find value in revisiting Novo Nordisk amid its prolonged share price weakness and robust cash flow forecasts.

Latest article

SiriusXM Stock Moves on Subscriber Surprise as Cash Flow Jumps

SiriusXM Stock Moves on Subscriber Surprise as Cash Flow Jumps

30 April 2026
Sirius XM Holdings lost 111,000 self-pay subscribers in Q1, far fewer than analysts expected, sending shares up 0.9% to $27.01. Revenue rose 1% to $2.09 billion, with net income up 20% to $245 million. Podcast revenue jumped 37%. SiriusXM ended the quarter with 32.8 million subscribers, down from 32.9 million a year earlier.
Iron Mountain Stock Jumps as AI Data-Center Demand Pushes 2026 Forecast Higher

Iron Mountain Stock Jumps as AI Data-Center Demand Pushes 2026 Forecast Higher

30 April 2026
Iron Mountain raised its 2026 revenue outlook after first-quarter revenue jumped 21.6% to $1.94 billion and net income rose to $149 million from $16 million. Shares surged 10% to $125.93. Data center revenue climbed 47% to $255 million, while asset lifecycle management revenue nearly doubled to $232 million. The company now expects 2026 revenue of $7.825–$7.925 billion.
Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

30 April 2026
Rezolve AI reported $60 million in first-quarter revenue, surpassing its audited 2025 total of $46.8 million, based on unaudited accounts. Shares rose 4.9% after the update. The company reaffirmed its $360 million 2026 revenue target and said it can reach profitability without new equity sales. Commerce.com, which rejected Rezolve’s all-stock takeover offer, adopted a poison pill defense.
Go toTop